New drug in the pipeline called Cabozantinib (XL184)

XL184 is a new drug that is being developed to treat metastatic prostate cancer in the bone. XL184 works by blocking the “angiogenesis,” or the growth of new blood vessels, to the tumor.

Dr. Barken reviews briefly information from the article published in Current Opinions in Urology, 2011.  Dr. Vogelzang brings his remarks about XL-184 ( Recent ASCO meeting)

Ongoing study      :Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer.  Location:

United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Matthew R Smith, MD, PhD     617-724-5257

For more information, click Here:

A new study about to start recruiting:  Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone.


Principal Investigator: David C. Smith, M.D. University of Michigan

More info: Please click here:

This entry was posted in Hormone Refractory Disease, Journal Club, Metastatic Disease, Metastatic Prostate Cancer Disease, Treatments for Prostate Cancer and tagged , . Bookmark the permalink.